BEST (Completed)
A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events
- Medicine
- bexagliflozin
- Population
- Diabetes mellitus
- Phase
- III
- Starting year
- 2015
- More information
- ClinivalTrials.gov